Donor defects after lymph vessel transplantation and free vascularized lymph node transfer: A comparison and evaluation of complications.
Da Vinci Xi
Donor side morbidity
Lymph surgery
Lymph vessel transfer
Robot-assisted surgery
Vascularized lymph node transfer
Journal
World journal of transplantation
ISSN: 2220-3230
Titre abrégé: World J Transplant
Pays: United States
ID NLM: 101608356
Informations de publication
Date de publication:
18 Apr 2021
18 Apr 2021
Historique:
received:
17
08
2020
revised:
02
01
2021
accepted:
12
03
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
7
5
2021
Statut:
ppublish
Résumé
Secondary lymphedema after surgical interventions is a progressive, chronic disease that is still not completely curable. Over the past years, a multitude of surgical therapy options have been described. To summarize the single-center complications in lymph vessel (LVTx) and free vascularized lymph node transfer (VLNT). In total, the patient collective consisted of 87 patients who were undergoing treatment for secondary leg lymphedema during the study period from March 2010 to April 2020. The data collection was performed preoperatively during consultations, as well as three weeks, six months and twelve months after surgical treatment. In the event of complications, more detailed follow-up checks were carried out. In total In total, 11 male and 76 female patients were operated on. The mean age of the patients at study entry was: omental VLNT: 57.45 ± 8.02 years; supraclavicular VLNT: 49.76 ± 4.16 years and LVTx: 49.75 ± 4.95 years. The average observation time postoperative was: omental VLNT: 18 ± 3.48 mo; supraclavicular VLNT: 14.15 ± 4.9 and LVTx: 14.84 ± 4.46 mo. In our omental VLNT, three patients showed a slight abdominal sensation of tension within the first 12 postoperative days. No other donor side morbidities occurred. No intraoperative conversion to open technique was needed. Our supraclavicular VLNT collective showed 10 lift defect morbidities with one necessary surgical intervention. In our LVTx collective, 12 cases of donor side morbidity were registered. In one case, surgical intervention was necessary. Concerning donor side morbidity, robot-assisted omental VLNT is clearly superior to supraclavicular lymph node transplantation and LVTx.
Sections du résumé
BACKGROUND
BACKGROUND
Secondary lymphedema after surgical interventions is a progressive, chronic disease that is still not completely curable. Over the past years, a multitude of surgical therapy options have been described.
AIM
OBJECTIVE
To summarize the single-center complications in lymph vessel (LVTx) and free vascularized lymph node transfer (VLNT).
METHODS
METHODS
In total, the patient collective consisted of 87 patients who were undergoing treatment for secondary leg lymphedema during the study period from March 2010 to April 2020. The data collection was performed preoperatively during consultations, as well as three weeks, six months and twelve months after surgical treatment. In the event of complications, more detailed follow-up checks were carried out. In total
RESULTS
RESULTS
In total, 11 male and 76 female patients were operated on. The mean age of the patients at study entry was: omental VLNT: 57.45 ± 8.02 years; supraclavicular VLNT: 49.76 ± 4.16 years and LVTx: 49.75 ± 4.95 years. The average observation time postoperative was: omental VLNT: 18 ± 3.48 mo; supraclavicular VLNT: 14.15 ± 4.9 and LVTx: 14.84 ± 4.46 mo. In our omental VLNT, three patients showed a slight abdominal sensation of tension within the first 12 postoperative days. No other donor side morbidities occurred. No intraoperative conversion to open technique was needed. Our supraclavicular VLNT collective showed 10 lift defect morbidities with one necessary surgical intervention. In our LVTx collective, 12 cases of donor side morbidity were registered. In one case, surgical intervention was necessary.
CONCLUSION
CONCLUSIONS
Concerning donor side morbidity, robot-assisted omental VLNT is clearly superior to supraclavicular lymph node transplantation and LVTx.
Identifiants
pubmed: 33954090
doi: 10.5500/wjt.v11.i4.129
pmc: PMC8058643
doi:
Types de publication
Journal Article
Langues
eng
Pagination
129-137Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: There are no conflicts of intrest to report.
Références
Arch Plast Surg. 2016 Mar;43(2):210-2
pubmed: 27019814
Scand J Plast Reconstr Surg. 1986;20(1):141-6
pubmed: 3775285
Br J Obstet Gynaecol. 1997 May;104(5):595-600
pubmed: 9166204
J Reconstr Microsurg. 2016 Jan;32(1):28-33
pubmed: 26372688
Plast Reconstr Surg Glob Open. 2020 Apr 24;8(4):e2505
pubmed: 32440389
Plast Reconstr Surg. 2015 Jun;135(6):1079e-1082e
pubmed: 25724055
J Reconstr Microsurg. 2016 Jan;32(1):50-5
pubmed: 26258914
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD006583
pubmed: 22336819
Clin Hemorheol Microcirc. 2019;73(1):53-63
pubmed: 31561341
Ann Surg. 2006 Mar;243(3):313-5
pubmed: 16495693
Microsurgery. 2012 Mar;32(3):171-7
pubmed: 22113994
Surg Gynecol Obstet. 1967 Sep;125(3):607-10
pubmed: 6035792
Ann Surg. 2008 Aug;248(2):259-65
pubmed: 18650636
Surg Today. 2008;38(12):1114-6
pubmed: 19039637
Aust N Z J Obstet Gynaecol. 2002 Aug;42(3):246-54
pubmed: 12230057
Ann Surg. 1974 Dec;180(6):847-9
pubmed: 4433169
J Surg Oncol. 2017 Jan;115(1):68-71
pubmed: 27449974
Microsurgery. 2017 Mar;37(3):197-205
pubmed: 26175309
Eur J Vasc Endovasc Surg. 2013 Mar;45(3):282-90
pubmed: 23273901
Plast Reconstr Surg. 2013 Jun;131(6):1286-1298
pubmed: 23714790
J Laparoendosc Adv Surg Tech A. 2012 May;22(4):362-70
pubmed: 22423957
Microsurgery. 2017 Jan;37(1):29-33
pubmed: 25771917